Introduction: Fingolimod is the first oral disease-modifying therapy (DMT) approved for relapsing-remitting multiple sclerosis (RRMS) (1). It works by modulating sphingosine-1-phosphate receptors to retain lymphocytes in lymph nodes, thereby reducing inflammation and the formation of new central nervous system lesions (1). Although fingolimod has d
460 Reached
Woman presented with Fever of Unknown Origin
7744 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35340 Reached151 Comments202 Likes
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Male with Jaw Pain and Abdominal Bloating
790 Reached24 Comments26 Likes
Case of Adolescent with Severe Macrocytic Anaemia
53253 Reached501 Comments51 Likes